Upgrade to SI Premium - Free Trial

Lilly (LLY) Says Detailed Results from 12-Month, Open-Label Phase 3 Study of Galcanezumab Will be Presented at IHC

September 8, 2017 6:47 AM
Eli Lilly and Company (NYSE: LLY) announced today that treatment with self-administered galcanezumab for up to 12 months ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles